End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Sector Update: Health Care Stocks Advance in Afternoon Trading | MT |
05-15 | CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study | MT |
Sales 2024 * | 19.8M 1.56B | Sales 2025 * | 46.48M 3.67B | Capitalization | 42.15M 3.33B |
---|---|---|---|---|---|
Net income 2024 * | -35M -2.77B | Net income 2025 * | -33M -2.61B | EV / Sales 2024 * | 2.13 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.91 x |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-1.52
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 01/04/19 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 31/08/18 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 31/12/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 01/04/19 |
Yue Wu
BRD | Director/Board Member | 62 | 31/03/13 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 20/03/23 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 694B | |
+30.77% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.77% | 239B | |
+9.13% | 209B | |
-3.97% | 209B | |
+9.27% | 169B |